A post hoc analysis of the phase 3 ATLAS trial showed that UGN-102 with or without TURBT induced meaningful disease-free survival and duration of response in patients with non–muscle-invasive bladder cancer.
"[Nivolumab] plus [gemcitabine-cisplatin] showed significant and clinically meaningful benefit in OS, PFS, and response over [gemcitabine-cisplatin] alone," said Guru Sonpavde, MD.
Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the 2024 AUA Annual Meeting.
"[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease," said Chiara Mercinelli, MD.
EG-70 is an experimental intravesical immunotherapy that does not involve viruses or integration. It aims to eliminate tumors by triggering coordinated innate and adaptive immune reactions specifically within the bladder.
Treatment with the Zenflow Spring System, a minimally invasive surgical therapy for the treatment of benign prostatic hyperplasia, does not cause negative sexual side effects.
"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.
Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs if they received leuprolide alone.
“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W. Dunn, MSN, NP-C, OCN, RN.
The addition of 18F-DCFPYL PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer in men on active surveillance.
Steerable ureteroscopic renal evacuation using the CVAC Aspiration System demonstrated noninferiority vs standard ureteroscopy for kidney stone removal, according to findings from the prospective, randomized ASPIRE trial.
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to the latest results from the phase 2b SUNRISE-1 trial.
Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
The UroActive artificial urinary sphincter devices were successfully implanted and activated in all patients.
“These findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate-and high-risk tumors,” said Nikhile Mookerji, MD.
Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.
Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
Qmax was also significantly improved, with a baseline of 7.7 mL/sec compared with 13.2 mL/sec at 4 years.
Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."
The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in three-fourths of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, according to findings from the phase 3 BOND-003 trial.
Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.
"Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence," says Jennifer Nguyen.
"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.
"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.
"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.
"We have to be intentional in order to design our trials so that we have a better participation of those groups," says Larissa V. Rodriguez, MD.
"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.
"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.
"A lot to be done in terms of moving PARP inhibitors earlier. Is that safe? Where do we get the most bang for our buck? And does the therapy have to be indefinite?" says Ashley E. Ross, MD, PhD.
